申请人:Ko Wun-Chang
公开号:US20060229358A1
公开(公告)日:2006-10-12
A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess selective phosphodiesterase 4 or 4/3 inhibition, as a main ingredient. Especially, this composition is used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), or chronic inflammation, and has bronchodilatory effects. In addition, whether the above-mentioned flavonoids have side effects, such as nausea, vomiting, gastric hypersecretion, etc., in accordance with their binding to high affinity rolipram binding sites (HARBS) of particulates of brain cells are disclosed.
本发明提供了一种药物组合物,其中药物组合物的主要成分含有具有选择性磷酸二酯酶 4 或 4/3 抑制作用的式 (I)、(II) 或 (III) 类黄酮。特别是,这种组合物用于治疗哮喘、慢性阻塞性肺病(COPD)或慢性炎症,具有支气管扩张作用。此外,还公开了上述黄酮类化合物与脑细胞微粒的高亲和力罗利普仑结合位点(HARBS)结合是否会产生副作用,如恶心、呕吐、胃分泌过多等。